<div id="subtitle">Novavax presents swine flu vaccine data at WHO conference, larger study in progress</div><div><p>Novavax Inc. said Friday it presented study results for its swine flu vaccine at The World Health Organization conference in Geneva.</p><p>In December, the company said the vaccine prompted an immune system response in patients during a midstage study being conducted in Mexico. Novavax has said its vaccine can be grown in weeks instead of the months it takes to make a traditional vaccine. Most flu vaccines are grown inside chicken eggs, but Novavax uses genetically engineered virus-like particles, which resemble a virus but do not have the genetic material a virus needs to reproduce itself.</p><p>The company has also said it does not expect U.S. approval of its vaccines for at least a few years.</p><p>The data being presented in Geneva shows the vaccine prompted immune responses at all doses tested. It is also presenting positive safety result. The study involved 1,000 healthy volunteers.</p><p>The company is conducting a larger, 3,000-person study.</p><img src="http://admatch-syndication.mochila.com/images/ad.gif?aid=69702818&bid=informcom" /></div><div id="copyright"><div>
Copyright 2010 <a href="http://www.ap.org">AP News</a></div></div>
Comments